Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.

Published

Journal Article

OBJECTIVE: The transglutaminase (TG) isoenzyme TG2, which catalyzes protein cross-linking via transamidation, influences healing phenotype in multiple forms of tissue injury. Moreover, TG2 knockout suppresses cartilage destruction but promotes osteophyte formation in instability-induced mouse knee osteoarthritis (OA). TG2 is marker of growth plate chondrocyte hypertrophy. Moreover, TG2 secreted by chondrocytes acts in part by promoting chondrocyte maturation to hypertrophy, a differentiation state linked with MMP-13 expression and disease progression in OA. Moreover, glucosamine, which is currently under investigation as an OA therapy, binds and inhibits TG2. Here, we examined TG2 as a potential marker of cartilage hypertrophy in the spontaneous guinea pig model of OA. METHODS: Synovial fluid ELISA and cartilage Immunohistochemistry and quantitative Reverse transcription-polymerase chain reaction (RT-PCR), were used to examine TG2 expression and TG transamidation-catalyzed isopeptide bonds. RESULTS: TG isopeptide bonds and TG2 were most abundant in articular cartilage in early knee OA. TG2 expression was robust at sites of early but not established osteophytes. Synovial fluid TG2 correlated with knee OA total histological score (r=0.47, P=0.01), as did medial tibial plateau cartilage TG2 mRNA (r=1.0, P=0.003). At 12 months of age, medial tibial plateau cartilage TG2 mRNA expression rose markedly in association with elevated type X collagen, as well as ADAMTS-5, and MMP-13 expression, changes not shared in age-matched Strain 13 guinea pigs that are less susceptible to knee OA. CONCLUSION: Hartley guinea pig knee TG2 expression associates with enhanced articular chondrocyte hypertrophy and is a biomarker of OA severity.

Full Text

Duke Authors

Cited Authors

  • Huebner, JL; Johnson, KA; Kraus, VB; Terkeltaub, RA

Published Date

  • August 2009

Published In

Volume / Issue

  • 17 / 8

Start / End Page

  • 1056 - 1064

PubMed ID

  • 19328881

Pubmed Central ID

  • 19328881

Electronic International Standard Serial Number (EISSN)

  • 1522-9653

Digital Object Identifier (DOI)

  • 10.1016/j.joca.2009.02.015

Language

  • eng

Conference Location

  • England